Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10964542rdf:typepubmed:Citationlld:pubmed
pubmed-article:10964542lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:10964542lifeskim:mentionsumls-concept:C0031307lld:lifeskim
pubmed-article:10964542lifeskim:mentionsumls-concept:C0019692lld:lifeskim
pubmed-article:10964542lifeskim:mentionsumls-concept:C0205341lld:lifeskim
pubmed-article:10964542lifeskim:mentionsumls-concept:C1514562lld:lifeskim
pubmed-article:10964542lifeskim:mentionsumls-concept:C1883221lld:lifeskim
pubmed-article:10964542lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:10964542lifeskim:mentionsumls-concept:C1883204lld:lifeskim
pubmed-article:10964542lifeskim:mentionsumls-concept:C1880389lld:lifeskim
pubmed-article:10964542lifeskim:mentionsumls-concept:C1956479lld:lifeskim
pubmed-article:10964542pubmed:issue3lld:pubmed
pubmed-article:10964542pubmed:dateCreated2000-9-22lld:pubmed
pubmed-article:10964542pubmed:abstractTextHuman immunodeficiency virus type 1 (HIV-1) envelope protein gp41 mediates viral fusion with human host cells. In this study we show that N36, a synthetic peptide derived from the N-terminus of gp41, induced directional migration and calcium mobilization in human monocytes and neutrophils. The activity of N36 on phagocytes was pertussis toxin sensitive, suggesting involvement of a Gi-coupled seven-transmembrane receptor(s). Since high concentrations of the bacterial chemotactic peptide fMet-Leu-Phe (fMLF) partially desensitized the calcium mobilizing activity of N36 in phagocytes, we postulated that N36 might use a low-affinity fMLF receptor. By using cells stably expressing fMLF receptor FPR or FPRL1, we demonstrate that N36 uses FPRL1 as a functional receptor. Our results suggest that HIV-1 gp41 may contain a fragment(s) that activates the innate host immune cells through FPRL1. Since the activation of FPRL1 in monocytes has been shown to heterologously desensitize chemokine receptors, the reduced phagocyte response to chemoattractants seen in AIDS patients may be attributed, at least in part, to heterologous desensitization.lld:pubmed
pubmed-article:10964542pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10964542pubmed:languageenglld:pubmed
pubmed-article:10964542pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10964542pubmed:citationSubsetIMlld:pubmed
pubmed-article:10964542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10964542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10964542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10964542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10964542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10964542pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10964542pubmed:statusMEDLINElld:pubmed
pubmed-article:10964542pubmed:monthSeplld:pubmed
pubmed-article:10964542pubmed:issn1521-6616lld:pubmed
pubmed-article:10964542pubmed:authorpubmed-author:DunlopN MNMlld:pubmed
pubmed-article:10964542pubmed:authorpubmed-author:KoDDlld:pubmed
pubmed-article:10964542pubmed:authorpubmed-author:TUPPlld:pubmed
pubmed-article:10964542pubmed:authorpubmed-author:MICClld:pubmed
pubmed-article:10964542pubmed:authorpubmed-author:HuJJlld:pubmed
pubmed-article:10964542pubmed:authorpubmed-author:JiangSSlld:pubmed
pubmed-article:10964542pubmed:authorpubmed-author:GongWWlld:pubmed
pubmed-article:10964542pubmed:authorpubmed-author:ShenWWlld:pubmed
pubmed-article:10964542pubmed:authorpubmed-author:Ming WangJJlld:pubmed
pubmed-article:10964542pubmed:copyrightInfoCopyright 2000 Academic Press.lld:pubmed
pubmed-article:10964542pubmed:issnTypePrintlld:pubmed
pubmed-article:10964542pubmed:volume96lld:pubmed
pubmed-article:10964542pubmed:ownerNLMlld:pubmed
pubmed-article:10964542pubmed:authorsCompleteYlld:pubmed
pubmed-article:10964542pubmed:pagination236-42lld:pubmed
pubmed-article:10964542pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:10964542pubmed:meshHeadingpubmed-meshheading:10964542...lld:pubmed
pubmed-article:10964542pubmed:meshHeadingpubmed-meshheading:10964542...lld:pubmed
pubmed-article:10964542pubmed:meshHeadingpubmed-meshheading:10964542...lld:pubmed
pubmed-article:10964542pubmed:meshHeadingpubmed-meshheading:10964542...lld:pubmed
pubmed-article:10964542pubmed:meshHeadingpubmed-meshheading:10964542...lld:pubmed
pubmed-article:10964542pubmed:meshHeadingpubmed-meshheading:10964542...lld:pubmed
pubmed-article:10964542pubmed:meshHeadingpubmed-meshheading:10964542...lld:pubmed
pubmed-article:10964542pubmed:meshHeadingpubmed-meshheading:10964542...lld:pubmed
pubmed-article:10964542pubmed:meshHeadingpubmed-meshheading:10964542...lld:pubmed
pubmed-article:10964542pubmed:meshHeadingpubmed-meshheading:10964542...lld:pubmed
pubmed-article:10964542pubmed:year2000lld:pubmed
pubmed-article:10964542pubmed:articleTitleN36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes.lld:pubmed
pubmed-article:10964542pubmed:affiliationLaboratory of Molecular Immunoregulation, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland, 21702, USA.lld:pubmed
pubmed-article:10964542pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10964542pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
entrez-gene:2358entrezgene:pubmedpubmed-article:10964542lld:entrezgene
entrez-gene:155971entrezgene:pubmedpubmed-article:10964542lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:10964542lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:10964542lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10964542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10964542lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10964542lld:pubmed